United States · Platforms & data · Stocktwits
CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month
Detailed summary
The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)
